BRPI0414622A - métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias - Google Patents

métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias

Info

Publication number
BRPI0414622A
BRPI0414622A BRPI0414622-0A BRPI0414622A BRPI0414622A BR PI0414622 A BRPI0414622 A BR PI0414622A BR PI0414622 A BRPI0414622 A BR PI0414622A BR PI0414622 A BRPI0414622 A BR PI0414622A
Authority
BR
Brazil
Prior art keywords
compound
pain treatment
methods
treatment methods
acute
Prior art date
Application number
BRPI0414622-0A
Other languages
English (en)
Inventor
Audra L Scully
Robert E Davis
Kimberly E Vanover
Luis Roberto Gardell
Jelveh Lameh
Nicholas Michael Kelly
Fabio Bertozzi
Vladimir Sherbukhin
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of BRPI0414622A publication Critical patent/BRPI0414622A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)

Abstract

"MéTODOS DE IDENTIFICAçãO DE COMPOSTOS, MéTODO DE SELEçãO DE COMPOSTO, MéTODOS DE TRATAMENTO DE DORES AGUDAS E CRÈNICAS, COMPOSTOS E MéTODOS DE TRATAMENTO DE DORES NEUROPáTICAS OU INFLAMATóRIAS". A invenção descrita abaixo refere-se à descoberta do subtipo receptor de neuropeptídeo FF que media a nocicepção aguda e dores neuropáticas crónicas, compostos que interagem seletivamente com esse subtipo receptor e métodos de tratamento de dores agudas e dores neuropáticas crónicas.
BRPI0414622-0A 2003-09-25 2004-09-24 métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias BRPI0414622A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50613003P 2003-09-25 2003-09-25
US50800803P 2003-10-02 2003-10-02
PCT/US2004/031530 WO2005031000A2 (en) 2003-09-25 2004-09-24 Treating neuropathic pain with neuropeptide ff receptor 2 agonists

Publications (1)

Publication Number Publication Date
BRPI0414622A true BRPI0414622A (pt) 2006-11-07

Family

ID=34396293

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414622-0A BRPI0414622A (pt) 2003-09-25 2004-09-24 métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias

Country Status (11)

Country Link
US (1) US20050136444A1 (pt)
EP (1) EP1687641A2 (pt)
JP (1) JP2007506435A (pt)
KR (1) KR20060088885A (pt)
AU (1) AU2004276812A1 (pt)
BR (1) BRPI0414622A (pt)
CA (1) CA2539753A1 (pt)
IL (1) IL174517A0 (pt)
MX (1) MXPA06003276A (pt)
RU (1) RU2006113941A (pt)
WO (1) WO2005031000A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1751553B1 (en) * 2004-05-24 2008-10-08 Ludwig-Maximilians-Universität München Identification of anti-prion drugs by high-throughput screening based on sift
WO2008014266A2 (en) * 2006-07-24 2008-01-31 University Of Maryland, Baltimore Heme oxygenase inhibitors and methods of therapeutic use
WO2008036858A2 (en) 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
US9675544B2 (en) 2008-01-22 2017-06-13 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
EP2470270A1 (en) * 2009-07-31 2012-07-04 AnaMar AB Compounds for treatment of inflammation
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
NZ713621A (en) * 2013-05-01 2020-07-31 Neoculi Pty Ltd Compounds and methods of treating infections
DK3164123T3 (da) 2014-07-02 2020-08-03 Inflectis Bioscience Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
PL3164391T3 (pl) 2014-07-02 2019-12-31 Inflectis Bioscience Pochodne O-alkilo-benzylidenoguanidyny i zastosowanie terapeutyczne w leczeniu zaburzeń związanych z akumulacją nieprawidłowo pofałdowanych białek
WO2016162689A1 (en) * 2015-04-08 2016-10-13 Medical Research Council Inhibitors and their uses
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
CA3049464A1 (en) 2017-02-14 2018-08-23 Research Triangle Institute Proline-based neuropeptide ff receptor modulators
WO2019215470A1 (en) 2018-05-09 2019-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
CA2233584A1 (en) * 1997-06-11 1998-12-11 Smithkline Beecham Corporation 7tm receptor hlwar77
US6262246B1 (en) * 1998-09-25 2001-07-17 Synaptic Pharmaceutical Corporation DNA encoding mammalian neuropeptides FF (NPFF) receptors and uses thereof
US20030176314A1 (en) * 2001-09-24 2003-09-18 Forray Carlos C. Compounds for the treatment of pain
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
EP1492883A2 (en) * 2002-04-02 2005-01-05 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)

Also Published As

Publication number Publication date
RU2006113941A (ru) 2007-10-27
KR20060088885A (ko) 2006-08-07
WO2005031000A3 (en) 2005-07-14
CA2539753A1 (en) 2005-04-07
US20050136444A1 (en) 2005-06-23
IL174517A0 (en) 2006-08-01
WO2005031000A2 (en) 2005-04-07
AU2004276812A1 (en) 2005-04-07
MXPA06003276A (es) 2006-06-08
JP2007506435A (ja) 2007-03-22
EP1687641A2 (en) 2006-08-09

Similar Documents

Publication Publication Date Title
BRPI0414622A (pt) métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias
LTPA2021516I1 (pt)
NO20033918L (no) Ny anvendelse av peptidklasse av forbindelser for behandling av allodyni eller andre typer av kronisk smerte eller fantomsmerte
ATE431833T1 (de) Verwendung einer peptidartigen verbindung zur behandlung von neuropathischen entzündlichen schmerzerscheinungen
BRPI0516533A (pt) método para o tratamento, inibição da progressão ou a erradicação da doença do rim policìstico em um mamìfero que dele necessita; produto; uso de um composto inibidor da tace; composição farmacêutica para o tratamento, a inibição da progressão ou a erradicação da doença do rim policìstico em um mamìfero
DK1355644T3 (da) Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
ECSP034600A (es) Compuestos de lactama
DK1420058T3 (da) Hurtig termisk processering af svære carbonhydrid-födeströmme i nærvære af calciumforbindelser
WO2003048207A3 (en) Anti-dota antibody
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DK1397164T3 (da) Lukkeelement
EA200601220A1 (ru) Анти-trkc антитела-агонисты и способы их применения
WO2006065273A3 (en) New human parvovirus
MA26252A1 (fr) Usine flottante de traitement d'hydrocarbures.
ATE370250T1 (de) Nachweis von pathogenen bakterien
HU0201394D0 (pt)
ATE455270T1 (de) Korrosionsbeständige leitungssysteme mit verbesserter oberflächenhärte
BR0215251A (pt) Sistema de limpeza úmido-seco
BRPI0412512A (pt) método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina
ITTO20010525A0 (it) Procedimento di trasmissione, ad esempio per la trasmissione ripartita di flussi audiovisivi o multimediali, sistema di trasmissione, trasme
BR0208784A (pt) Método para tratar, inibir a progressão ou erradicar a doença renal policìstica em um mamìfero em necessidade do mesmo
DE50200864D1 (de) Verbundelemente enthaltend bitumen
Goebbert Atmospheric teleconnections and Australian region tropical cyclone variability 1970–2005
MA24917A1 (fr) Machine electromecanique pour l'injection d'enduit, fait pour la construction d'immeubles.
FR2832646B1 (fr) Separateur destine au traitement de l'eau chargee, notamment en hydrocarbures ou en boues

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.